Dengue
Also known as: Break-bone fever, Dengue fever
Methodology & AI Transparency ⓘ
Dengue Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is dengue? Dengue is a viral infection .
- 2 Real-world patient consensus: Synonyms for Dengue (A90): Break-bone fever, Dengue fever (Fertility & Pregnancy).
- 3 Typical cash cost range: Differential triage of Dengue (A90) utilizes fetal growth surveillance in Dengue (A90: with OB/GYN or).
- 4 Top reported side effects / signs: Key Fertility & Pregnancy biomarkers for Dengue (A90): Prenatal TSH, Ferritin in Dengue (A90: & Glucose Screen) & Anti-Mullerian Hormone (AMH) in Dengue (A90: & Day-3 FSH) (Age-contextual ovarian reserve (A90)).
Ask our AI Specialists anything about Dengue
What Is Dengue?
What is dengue? Dengue is a viral infection . It can be caused by four related viruses. You can get it if an infected mosquito bites you. It is common in warm, wet areas of the world. Although rare, it can be found in some parts of the United States. Outbreaks are more common during rainy seasons. How does dengue spread? Dengue spreads to people through the bite of an infected mosquito. It does not spread directly from person to person. However, the infection can be passed to the baby during pregnancy. In rare cases, it can spread through a blood transfusion , organ transplant , or needle stick injury (an accidental injury from a used needle)..
Pathophysiology, Underlying Causes & Clinical Presentation
Dengue (A90) alters fertility & pregnancy homeostasis through ovulatory hypothalamic-pituitary-gonadal axis in Dengue (A90: disruption); Cross-referenced with NIH MeSH (Dengue), clinical remission targets Anti-Mullerian Hormone (AMH) in Dengue (A90: & Day-3 FSH) within Age-contextual ovarian reserve (A90).
Common Symptoms & Clinical Signs
- • Nausea and vomiting
- • Aches and pains (eye pain, usually behind the eyes, and pain in the muscles, joints, or bones)
- • Presentation of Dengue (A90): inability to achieve in Dengue (A90: clinical pregnancy after)
- • Secondary Dengue clinical sign: irregular luteal phase in Dengue (A90: timing, anovulatory cycles,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dengue Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Fertility, Pregnancy & Postpartum Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Prenatal TSH, Ferritin in Dengue (A90: & Glucose Screen) | Trimester-specific clinical range (A90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Anti-Mullerian Hormone (AMH) in Dengue (A90: & Day-3 FSH) | Age-contextual ovarian reserve (A90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Maternal Blood Pressure in Dengue (A90: & Urine Protein) | BP < 120/80 mmHg; negative proteinuria (A90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dengue
Treatment selection for Dengue depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dengue)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children: What a 3,765-Participant Study Found The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. The Journal of infectious diseases • 2025-07-11 • Phase III Randomized Trial | N = 3,765 | 96/100 | PMID 40100744 ↗ |
| New Insights on Phase 3 trial of the immunogenicity and safety of getting both at the same time: What a 900-Participant Study Found Immune responses following getting both at the same time of HAV vaccine and TAK-003 were non-inferior to administration of HAV vaccine alone. Vaccine • 2023-02-10 • Phase III Randomized Trial | N = 900 | 93/100 | PMID 36681529 ↗ |
| New Insights on Randomized, gold-standard blind, compared against a dummy pill (placebo), phase 3: What a 700-Participant Study Found Three lots of simplified formulation were safe and achieved the endpoint of equivalence of lots. Vaccine • 2025-11-14 • Phase III Randomized Trial | N = 700 | 93/100 | PMID 41092804 ↗ |
| New Insights on Immunogenicity and safety of concomitant and sequential administration of yellow: What a 900-Participant Study Found In this study, YF-17D vaccine and TAK-003 were immunogenic and well tolerated when sequentially or concomitantly administered. PLoS neglected tropical diseases • 2023-03-15 • Phase III Randomized Trial | N = 900 | 93/100 | PMID 36888687 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children This exploratory analysis shows TAK-003 was efficacious in dengue prevention across age groups in children and adolescents 4-16 years of age living in dengue endemic areas. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2025-02-05 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38995684 ↗ |
Dengue Patient Community & “People Like Me” Threads
Filter Dengue community threads and patient logs by age, biological sex, dosage, and treatment duration.